Clinical Trials Browser

Unknown × pembrolizumab × Clear all

NCT05763004 2024-10-08

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Phase 1 Unknown

Other solid neoplasm

Solid Tumor, Adult

NCT06270706 2024-06-12

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03425565 2024-04-12

PEACOCC

Phase 2 Unknown

Clear Cell Tumor

NCT05567588 2024-02-01

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

Phase 2 Unknown

Clear-cell metastatic renal cell carcinoma

NCT03789097 2024-01-30

Vaccination With Flt3L, Radiation, and Poly-ICLC

Phase 1/2 Unknown

BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT03532737 2024-01-23

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Phase 2 Unknown

Head and Neck Neoplasms

NCT04224480 2024-01-19

Longitudinal Immune-phenotyping of HCC Following MK-3475

Phase 1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT06204614 2024-01-12

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Unknown

Muscle Invasive Bladder Urothelial Carcinoma

NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Phase 1/2 Unknown

Melanoma

NCT04294576 2023-11-09

FIH

Phase 1 Unknown

Other solid neoplasm

Locally Advanced/Metastatic Solid Tumors

NCT03458455 2023-11-01

TREATMENT

Brain Neoplasms

NCT06100796 2023-10-25

NSCLC

Diabetes Mellitus

NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Phase 1/2 Unknown

Melanoma

NCT05986331 2023-09-21

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Phase 3 Unknown

Melanoma

NCT05418660 2023-09-18

I-STOP

Carcinoma, Non-Small-Cell Lung

NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Phase 1 Unknown

Lymphoma, Neoplasms, Neoplasms, Experimental

NCT02858921 2023-08-30

Neo Trio

Phase 2 Unknown

Melanoma, Neoplasms

NCT05578664 2023-08-30

PE-PE

Phase 2 Unknown

Oligometastatic Renal Cell Carcinoma

NCT03331731 2023-08-21

PLIMATH

Phase 2 Unknown

Hodgkin Disease

NCT04262687 2023-08-18

POCHI

Phase 2 Unknown

Gastrointestinal

Colorectal Cancer Metastatic

NCT05739006 2023-08-02

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Phase 1 Unknown

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Phase 1/2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

NCT05127590 2023-07-03

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Phase 1/2 Unknown

Advanced Squamous Non-Small Cell Lung Carcinoma

NCT03077828 2023-06-02

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

43 enrolled 9 charts

Hodgkin Disease

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03280667 2023-03-29

KEYPAD

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03132675 2023-03-27

Keynote-695

Phase 2 Unknown

Melanoma

NCT03410784 2023-03-24

MITO28MaNGOov4

Phase 2 Unknown

Ovarian Neoplasms

NCT04396457 2023-03-23

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Phase 2 Unknown

Lung Neoplasms

NCT04638582 2023-03-22

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05761132 2023-03-09

Apollo

Phase 2 Unknown

Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT05175235 2023-03-03

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Phase 1/2 Unknown

Neoplasms

NCT05201612 2023-02-24

PEMBROLA

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04359199 2023-02-10

QUASAR

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT03099564 2023-02-06

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Phase EARLY_PHASE1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05578170 2023-02-03

PROBES

Squamous Cell Carcinoma of Head and Neck

NCT03430700 2023-01-30

PROMPT

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05700955 2023-01-26

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

Phase 1 Unknown

Glioblastoma

NCT05681728 2023-01-12

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05647954 2022-12-13

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Phase 3 Unknown

DermatologicEndocrineNET

Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Unknown

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05578222 2022-10-13

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

Phase 2 Unknown

NSCLC With COPD

NCT05551767 2022-09-23

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

Phase 2 Unknown

Head and Neck Neoplasms

NCT04913025 2022-09-21

REFINE

Phase 2 Unknown

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT04571632 2022-09-14

Luscid

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04641728 2022-08-09

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Phase 2 Unknown

Gastrointestinal

PD-1 Antibody